Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

被引：0
|
作者：
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Templeton, Ian
Passamonti, Francesco
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4179
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of hydro-mechanical defragmentation in intermediate- and high-risk pulmonary embolism
    Hassan, Ayman K. M.
    Ahmed, Heba
    Ahmed, Yousef
    Elfadl, Abd-Elazim Abo
    Omar, Amany
    EGYPTIAN HEART JOURNAL, 2021, 73 (01):
  • [32] Efficacy and safety of hydro-mechanical defragmentation in intermediate- and high-risk pulmonary embolism
    Ayman K. M. Hassan
    Heba Ahmed
    Yousef Ahmed
    Abd-Elazim Abo Elfadl
    Amany Omar
    The Egyptian Heart Journal, 73
  • [33] Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Koschmieder, Steffen
    Harrison, Claire N.
    Cervantes, Francisco
    Heidel, Florian H.
    Drummond, Mark
    Rey, Jerome
    Hurh, Eunju
    Bao, Weichao
    Rampersad, Anita
    Kalambakas, Stacey
    Vannucchi, Alessandro Maria
    BLOOD, 2014, 124 (21)
  • [34] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit K.
    Ali, Haris
    Wang, Eunice
    Gerds, Aaron T.
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen T.
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2022, 140
  • [35] Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis
    Mascarenhas, John
    Saab, Rabih
    Brackman, Deanna
    Modi, Dimple A.
    Abraham, Linu
    Ward, James E.
    Verstovsek, Srdan
    BLOOD, 2020, 136
  • [36] Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients
    Siragusa, Sergio
    Passamonti, Francesco
    Cervantes, Francisco
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (03) : 140 - 143
  • [37] Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
    Harrison, Claire N.
    Garcia, Jacqueline S.
    Mesa, Ruben A.
    Somervaille, Tim C. P.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Holes, Leanne
    Jia, Jia
    Harb, Jason
    Hutti, Jessica
    Prchal, Josef T.
    BLOOD, 2019, 134
  • [38] Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Ohanian, Maro N.
    Zhou, Lingsha
    Pierce, Sherry A.
    Gergis, Romany
    Borthakur, Gautam
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Daver, Naval G.
    BLOOD, 2018, 132
  • [39] Updated Results of a Phase 2 Study of Ruxolitinib in Combination With 5-Azacitidine in Patients With Myelofibrosis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 12 - 13
  • [40] Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
    Harrison, Claire
    Schaap, Nicolaas
    Vannucchi, Alessandro
    Kiladjian, Jean-Jacques
    Jourdan, Eric
    Silver, Richard
    Schouten, Harry
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Gerike, Torsten
    Rose, Shelonitda
    Li, Mingyu
    Berry, Tymara
    Brownstein, Carrie
    Mesa, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S356 - S356
12345